Abstract
First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have